{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:49:22Z","timestamp":1760150962510,"version":"build-2065373602"},"reference-count":89,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Thrombotic microangiopathy (TMA) gathers consumptive thrombocytopenia, mechanical haemolytic anemia, and organ damage. Hemolytic uremic syndromes (HUS) are historically classified as primary or secondary to another disease once thrombotic thrombocytopenic purpura (TTP), Shiga-toxin HUS, and cobalamin C-related HUS have been ruled out. Complement genetics studies reinforced the link between complement dysregulation and primary HUS, contributing to reclassifying some pregnancy- and\/or post-partum-associated HUS and to revealing complement involvement in severe and\/or refractory hypertensive emergencies. By contrast, no firm evidence allows a plausible association to be drawn between complement dysregulation and Shiga-toxin HUS or other secondary HUS. Nevertheless, rare complement gene variants are prevalent in healthy individuals, thus providing an indication that an investigation into complement dysregulation should be carefully balanced and that the results should be cautiously interpreted with the help of a trained geneticist. Several authors have suggested reclassifying HUS in two entities, regardless of they are complement-mediated or not, since the use of eculizumab, an anti-C5 antibody, dramatically lowers the proportion of patients who die or suffer from end-stage renal disease within the year following diagnosis. Safety and the ideal timing of eculizumab discontinuation is currently under investigation, and the long-term consequences of HUS should be closely monitored over time once patients exit emergency departments.<\/jats:p>","DOI":"10.3390\/jcm11030790","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T09:59:21Z","timestamp":1643709561000},"page":"790","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2942-7350","authenticated-orcid":false,"given":"Renaud","family":"Pr\u00e9vel","sequence":"first","affiliation":[{"name":"CHU Bordeaux, Medical Intensive Care Unit, F-33000 Bordeaux, France"},{"name":"University Bordeaux, Centre de Recherche Cardio-Thoracique de Bordeaux, Inserm UMR 1045, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5814-3122","authenticated-orcid":false,"given":"Yahsou","family":"Delmas","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Nephrology Transplantation Dialysis Apheresis Unit, F-33076 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivien","family":"Guillotin","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Medical Intensive Care Unit, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Gruson","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Medical Intensive Care Unit, F-33000 Bordeaux, France"},{"name":"University Bordeaux, Centre de Recherche Cardio-Thoracique de Bordeaux, Inserm UMR 1045, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Rivi\u00e8re","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Internal Medicine Department, F-33000 Bordeaux, France"},{"name":"University Bordeaux, Biology of Cardiovascular Diseases, InsermU1034, F-33604 Pessac, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic Uraemic Syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of Thrombotic Micro-angiopathy","volume":"371","author":"George","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal Complement Inhibitor Eculizumab in Adult Patients with Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Timmermans, S.A.M.E.G., and van Paassen, P. (2021). The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation. J. Clin. Med., 10.","DOI":"10.3390\/jcm10143034"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in Secondary Atypical Haemolytic Uraemic Syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and Secondary Hemolytic Uremic Syndromes Have a Distinct Presentation and No Common Genetic Risk Factors","volume":"95","author":"Delmas","year":"2019","journal-title":"Kidney Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/00007890-200203150-00017","article-title":"De Novo Hemolytic Uremic Syndrome after Kidney Transplantation in Patients Treated with Cyclosporine-Sirolimus Combination","volume":"73","author":"Langer","year":"2002","journal-title":"Transplantation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/j.1600-6143.2010.03178.x","article-title":"De Novo Thrombotic Microangiopathy in Renal Allograft Biopsies-Role of Antibody-Mediated Rejection","volume":"10","author":"Satoskar","year":"2010","journal-title":"Am. J. Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ajkd.2003.07.008","article-title":"Thrombotic Microangiopathy after Renal Transplantation in the United States","volume":"42","author":"Reynolds","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic Syndrome","volume":"13","author":"Zuber","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement Mutation-Associated de Novo Thrombotic Microangiopathy Following Kidney Transplantation","volume":"8","author":"Lionet","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2019040331","article-title":"Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome","volume":"30","author":"Zuber","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1111\/ajt.15364","article-title":"Safety and Efficacy of Eculizumab in the Prevention of Antibody-Mediated Rejection in Living-Donor Kidney Transplant Recipients Requiring Desensitization Therapy: A Randomized Trial","volume":"19","author":"Marks","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2215\/CJN.00280117","article-title":"Hemolytic Uremic Syndrome in Pregnancy and Postpartum","volume":"12","author":"Bruel","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.kint.2017.06.022","article-title":"A Retrospective Study of Pregnancy-Associated Atypical Hemolytic Uremic Syndrome","volume":"93","author":"Huerta","year":"2018","journal-title":"Kidney Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.2020005221","article-title":"Management of Thrombotic Microangiopathy in Pregnancy and Postpartum: Report from an International Working Group","volume":"136","author":"Fakhouri","year":"2020","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bjh.16626","article-title":"The Natural Course of Pregnancies in Women with Primary Atypical Haemolytic Uraemic Syndrome and Asymptomatic Relatives","volume":"190","author":"Timmermans","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1681\/ASN.2016090995","article-title":"Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome","volume":"29","author":"Gaggl","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2215\/CJN.05830519","article-title":"Complement Activation and Thrombotic Microangiopathies","volume":"14","author":"Palomo","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria","volume":"373","author":"Kelly","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/ndt\/gfw314","article-title":"Atypical Haemolytic Uraemic Syndrome and Pregnancy: Outcome with Ongoing Eculizumab","volume":"31","author":"Servais","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_26","first-page":"1421","article-title":"Eculizumab for the Treatment of Pregnancy-Related Atypical Hemolytic Uremic Syndrome","volume":"93","author":"Castro","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40620-015-0173-5","article-title":"Eculizumab in Pregnancy-Associated Atypical Hemolytic Uremic Syndrome: Insights for Optimizing Management","volume":"28","author":"Blasco","year":"2015","journal-title":"J. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/ckj\/sfs185","article-title":"Post-Partum Atypical Haemolytic-Uraemic Syndrome Treated with Eculizumab: Terminal Complement Activity Assessment in Clinical Practice","volume":"6","author":"Delmas","year":"2013","journal-title":"Clin. Kidney J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-159-1-201307020-00023","article-title":"Successful Treatment of the Postpartum Atypical Hemolytic Uremic Syndrome with Eculizumab","volume":"159","author":"Zschiedrich","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive Value of the SFlt-1:PlGF Ratio in Women with Suspected Preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"w20533","DOI":"10.4414\/smw.2021.20533","article-title":"The Role of SFlt1\/PlGF Ratio in the Assessment of Preeclampsia and Pregnancy-Related Hypertensive Disorders","volume":"151","author":"Baert","year":"2021","journal-title":"Swiss Med. Wkly."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2019.216903","article-title":"Impact of Hypertensive Emergency and Rare Complement Variants on the Presentation and Outcome of Atypical Hemolytic Uremic Syndrome","volume":"104","author":"Boudhabhay","year":"2019","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.kint.2019.05.014","article-title":"Severe and Malignant Hypertension Are Common in Primary Atypical Hemolytic Uremic Syndrome","volume":"96","author":"Cavero","year":"2019","journal-title":"Kidney Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/HJH.0000000000001913","article-title":"Malignant Hypertension: Diagnosis, Treatment and Prognosis with Experience from the Bordeaux Cohort","volume":"37","author":"Rubin","year":"2019","journal-title":"J. Hypertens."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1097\/01.hjh.0000249710.21146.38","article-title":"Ethnic Disparities in the Incidence, Presentation and Complications of Malignant Hypertension","volume":"24","author":"Koopmans","year":"2006","journal-title":"J. Hypertens."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1097\/HJH.0000000000001446","article-title":"Predictors of 5-Year Outcomes in Malignant Phase Hypertension: The West Birmingham Malignant Hypertension Registry","volume":"35","author":"Shantsila","year":"2017","journal-title":"J. Hypertens."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/modpathol.2017.154","article-title":"Genetic Testing of Complement and Coagulation Pathways in Patients with Severe Hypertension and Renal Microangiopathy","volume":"31","author":"Larsen","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/HYPERTENSIONAHA.115.05241","article-title":"Increasing Trend in Admissions for Malignant Hypertension and Hypertensive Encephalopathy in the United States","volume":"65","author":"Polgreen","year":"2015","journal-title":"Hypertension"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/ehjcvp\/pvy032","article-title":"ESC Council on Hypertension Position Document on the Management of Hypertensive Emergencies","volume":"5","author":"Lip","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/ajh.2009.153","article-title":"Improving Survival of Malignant Hypertension Patients over 40 Years","volume":"22","author":"Lane","year":"2009","journal-title":"Am. J. Hypertens."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/00004872-199508000-00013","article-title":"Complications and Survival of 315 Patients with Malignant-Phase Hypertension","volume":"13","author":"Lip","year":"1995","journal-title":"J. Hypertens."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/HYPERTENSIONAHA.119.13714","article-title":"Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy","volume":"75","author":"Timmermans","year":"2020","journal-title":"Hypertension"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000151620.17905.ee","article-title":"Microangiopathic Hemolysis and Renal Failure in Malignant Hypertension","volume":"45","author":"Honnebier","year":"2005","journal-title":"Hypertension"},{"key":"ref_44","first-page":"e11","article-title":"Acute Severe Hypertension","volume":"382","author":"Rubin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1093\/ndt\/gfq143","article-title":"Long-Term Renal Survival in Malignant Hypertension","volume":"25","author":"Morales","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1681\/ASN.2018020184","article-title":"C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension","volume":"29","author":"Timmermans","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","article-title":"Patients with Hypertension-Associated Thrombotic Microangiopathy May Present with Complement Abnormalities","volume":"91","author":"Timmermans","year":"2017","journal-title":"Kidney Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-1809.2009.00554.x","article-title":"Epidemiological Approach to Identifying Genetic Predispositions for Atypical Hemolytic Uremic Syndrome","volume":"74","author":"Sullivan","year":"2010","journal-title":"Ann. Hum. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and Outcome of Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children and Adults","volume":"8","author":"Fakhouri","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative Role of Genetic Complement Abnormalities in Sporadic and Familial AHUS and Their Impact on Clinical Phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1681\/ASN.2015040385","article-title":"High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies","volume":"27","author":"Bu","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","article-title":"Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy","volume":"200","author":"Osborne","year":"2018","journal-title":"J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","article-title":"Clinical and Genetic Predictors of Atypical Hemolytic Uremic Syndrome Phenotype and Outcome","volume":"94","author":"Schaefer","year":"2018","journal-title":"Kidney Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic Microangiopathy in AHUS and beyond: Clinical Clues from Complement Genetics","volume":"17","author":"Fakhouri","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/ndt\/14.5.1229","article-title":"Familial Relapsing Haemolytic Uraemic Syndrome and Complement Factor H Deficiency","volume":"14","author":"Warwicker","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"12966","DOI":"10.1073\/pnas.2135497100","article-title":"Mutations in Human Complement Regulator, Membrane Cofactor Protein (CD46), Predispose to Development of Familial Hemolytic Uremic Syndrome","volume":"100","author":"Richards","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/S0140-6736(03)14742-3","article-title":"Familial Haemolytic Uraemic Syndrome and an MCP Mutation","volume":"362","author":"Noris","year":"2003","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/jmg.2005.030783","article-title":"The Development of Atypical Haemolytic-Uraemic Syndrome Is Influenced by Susceptibility Factors in Factor H and Membrane Cofactor Protein: Evidence from Two Independent Cohorts","volume":"42","author":"Kemp","year":"2005","journal-title":"J. Med. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1136\/jmg.2004.019083","article-title":"Complement Factor I: A Susceptibility Gene for Atypical Haemolytic Uraemic Syndrome","volume":"41","author":"Blouin","year":"2004","journal-title":"J. Med. Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in Complement C3 Predispose to Development of Atypical Hemolytic Uremic Syndrome","volume":"112","author":"Miller","year":"2008","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-Function Mutations in Complement Factor B Are Associated with Atypical Hemolytic Uremic Syndrome","volume":"104","author":"Harris","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of Complement Activation in AHUS and How to Monitor Eculizumab Therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive Genetic Analysis of Complement and Coagulation Genes in Atypical Hemolytic Uremic Syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","article-title":"Factor H Autoantibodies in Atypical Hemolytic Uremic Syndrome Correlate with CFHR1\/CFHR3 Deficiency","volume":"111","author":"Licht","year":"2008","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical AHUS: State of the Art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.2020006931","article-title":"Familial Risk of Developing Atypical Hemolytic-Uremic Syndrome","volume":"136","author":"Arjona","year":"2020","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.kint.2017.07.015","article-title":"Complete Functional Characterization of Disease-Associated Genetic Variants in the Complement Factor H Gene","volume":"93","author":"Merinero","year":"2018","journal-title":"Kidney Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1681\/ASN.2013070796","article-title":"Complement Factor B Mutations in Atypical Hemolytic Uremic Syndrome-Disease-Relevant or Benign?","volume":"25","author":"Marinozzi","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The Long-Acting C5 Inhibitor, Ravulizumab, Is Effective and Safe in Adult Patients with Atypical Hemolytic Uremic Syndrome Na\u00efve to Complement Inhibitor Treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The Long-Acting C5 Inhibitor, Ravulizumab, Is Effective and Safe in Pediatric Patients with Atypical Hemolytic Uremic Syndrome Na\u00efve to Complement Inhibitor Treatment","volume":"100","author":"Ariceta","year":"2021","journal-title":"Kidney Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and Safety of Eculizumab in Atypical Hemolytic Uremic Syndrome from 2-Year Extensions of Phase 2 Studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(15)00076-8","article-title":"Adult-Onset Renal Thrombotic Microangiopathy and Pulmonary Arterial Hypertension in Cobalamin C Deficiency","volume":"386","author":"Bekri","year":"2015","journal-title":"Lancet"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in Paroxysmal Nocturnal Haemoglobinuria and Atypical Haemolytic Uraemic Syndrome: 10-Year Pharmacovigilance Analysis","volume":"185","author":"Marantz","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0022-3476(96)70436-5","article-title":"Invasive Haemophilus Influenzae Type b Infection in a Child with Familial Deficiency of the Beta Subunit of the Eighth Component of Complement","volume":"128","author":"Pallares","year":"1996","journal-title":"J. Pediatr."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1749-6632.2009.04633.x","article-title":"Clinical Significance of Complement Deficiencies","volume":"1173","author":"Pettigrew","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00467-011-1929-3","article-title":"Insufficient Protection by Neisseria Meningitidis Vaccination Alone during Eculizumab Therapy","volume":"26","author":"Bouts","year":"2011","journal-title":"Pediatr. Nephrol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cmi.2017.07.011","article-title":"Post-Eculizumab Meningococcaemia in Vaccinated Patients","volume":"24","author":"Lebel","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/S0264-410X(03)00440-7","article-title":"Long Term Effects of Vaccination of Patients Deficient in a Late Complement Component with a Tetravalent Meningococcal Polysaccharide Vaccine","volume":"21","author":"Platonov","year":"2003","journal-title":"Vaccine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/INF.0b013e3182503849","article-title":"Gonococcal Septic Shock Associated with Eculizumab Treatment","volume":"31","author":"Gleesing","year":"2012","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/OLQ.0000000000000202","article-title":"Disseminated Gonococcal Infection and Eculizumab\u2014A \u201cHigh Risk\u201d Connection?","volume":"41","author":"Hublikar","year":"2014","journal-title":"Sex Transm. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of Eculizumab Treatment in Atypical Hemolytic Uremic Syndrome: An Update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab Cessation in Atypical Hemolytic Uremic Syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab Discontinuation in Children and Adults with Atypical Hemolytic-Uremic Syndrome: A Prospective Multicenter Study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Sukumar, S., Brodsky, M.A., Hussain, S., Yanek, L.R., Moliterno, A.R., Brodsky, R.A., Cataland, S.R., and Chaturvedi, S. (2021). Cardiovascular Disease Is a Leading Cause of Mortality among TTP Survivors in Clinical Remission. Blood Adv., 6.","DOI":"10.1182\/bloodadvances.2020004169"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.revmed.2020.12.011","article-title":"[Endothelial dysfunction in thrombotic thrombocytopenic purpura: Therapeutic perspectives]","volume":"42","author":"Prevel","year":"2021","journal-title":"Rev. Med. Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood.2019000748","article-title":"Prognostic and Long-Term Survival of Immune Thrombotic Thrombocytopenic Purpura in Older Patients","volume":"134","author":"Prevel","year":"2019","journal-title":"Blood"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/3\/790\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:12:23Z","timestamp":1760134343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/3\/790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":89,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["jcm11030790"],"URL":"https:\/\/doi.org\/10.3390\/jcm11030790","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}